📷 Image: Wikimedia Commons / Bollywood Hungama
Business
Aarti Drugs' Baddi Plant Receives 3 FDA Form 483 Observations
✍️ CNBC TV18
🗓 07 Nov 2026, 01:17 AM
👁 19
The US Food and Drug Administration has issued three Form 483 observations at Aarti Drugs' Baddi facility in Himachal Pradesh, highlighting compliance concerns.
The U.S. Food and Drug Administration (FDA) has issued three Form 483 observations at Aarti Drugs' Baddi facility in Himachal Pradesh, indicating that the plant failed to meet certain regulatory requirements during a recent inspection.
The Baddi site is one of the company’s key manufacturing hubs, producing a range of pharmaceutical products for both domestic and international markets.
A Form 483 is a notice of inspection observations that the FDA issues when it identifies potential violations of the Federal Food, Drug, and Cosmetic Act. The observations serve as a warning that corrective action is needed.
Aarti Drugs has not yet released a statement, but industry analysts expect the company to respond promptly and address the FDA’s concerns to avoid further regulatory action.
The Baddi site is one of the company’s key manufacturing hubs, producing a range of pharmaceutical products for both domestic and international markets.
A Form 483 is a notice of inspection observations that the FDA issues when it identifies potential violations of the Federal Food, Drug, and Cosmetic Act. The observations serve as a warning that corrective action is needed.
Aarti Drugs has not yet released a statement, but industry analysts expect the company to respond promptly and address the FDA’s concerns to avoid further regulatory action.